No Data
Beijing Hotgen Biotech Co.,Ltd (688068.SH) plans to increase its investment in the associated company Shunji Pharmaceutical.
On April 22, Gelonghui reported that Beijing Hotgen Biotech Co., Ltd (688068.SH) announced plans to increase capital in its affiliated company Shunjing Pharmacy with cash contributions from Songhe Fund, Dacheng Fund, Chuangjing Kangrun, Chuangjing Shunze, and Lishui Qiuda. The capital increase price is 25 yuan per registered capital, with a total amount of 300 million yuan. The company will contribute 133 million yuan from its own funds for this capital increase. After the completion of this capital increase, the registered capital of Shunjing Biotech will increase from the original 60 million yuan to 72 million yuan, and the company's equity stake in Shunjing Pharmacy will decrease from 45.8333% to 45.583%.
Brokerage morning meeting highlights: The USA has increased tariffs on China, but the impact on these industries in the A-shares may be limited.
In today's brokerage morning meeting, GF SEC believes that the USA's tariffs on China have a limited impact on the A-share Computer Industry; China Securities Co.,Ltd. suggested being Bullish on the Innovative Drugs industry that is currently not affected by tariffs; Galaxy Securities stated that Deep Sea Technology has entered a new stage in Global Strategy, focusing on opportunities in core equipment.
Beijing Hotgen Biotech Co.,Ltd (688068.SH): Recently obtained 30 overseas qualification certifications.
On March 25, Glonghui reported that Beijing Hotgen Biotech Co.,Ltd (688068.SH) announced that the company and its subsidiaries recently obtained 30 overseas certification qualifications. The acquisition of these qualifications has enriched the variety of the company's products, further improved the menu of the company's in vitro diagnostic products, and actively responded to the demands of the overseas market, facilitating the enhancement of the company's market expansion capabilities and strengthening its core competitiveness.
Express News | Sungen Biomedical's World-First New Drug Sgc001 Monoclonal Antibody Receives FDA Fast Track Approval
Hejing Biotech: Beijing Hejing Biotechnology Co., Ltd. 2024 Annual Performance Report Announcement
Beijing Hejing Biotechnology Co., Ltd. 2024 Annual Performance Report Announcement
